Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study

Cancer

Volumn 122, Issue 9, 2016, Pages 1434-1443

  Meulendijks, Didier ^a   De Groot, Jan Willem B ^b   Los, Maartje ^c   Boers, James E ^b   Beerepoot, Laurens V ^d   Polee, Marco B ^e   Beeker, Aart ^f   Portielje, Johanna E A ^g   Goey, Swan H ^d   De Jong, Robert S ^h   Vanhoutvin, Steven A L W ^a   Kuiper, Maria ^a   Sikorska, Karolina ^a   Pluim, Dick ^a   Beijnen, Jos H ^a,i   Schellens, Jan H M ^a,i   Grootscholten, Cecile ^a   Tesselaar, Margot E T ^a   Cats, Annemieke ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b Isala ^*  (Netherlands)

^c ST ANTONIUS HOSPITAL   (Netherlands)

^d Microvida Laboratory for Medical Microbiology and Immunology   (Netherlands)

^e MEDICAL CENTER LEEUWARDEN   (Netherlands)

^f Department of Orthopaedic Surgery   (Netherlands)

^g HAGA HOSPITAL   (Netherlands)

^h MARTINI HOSPITAL   (Netherlands)

ⁱ UTRECHT UNIVERSITY   (Netherlands)

Author keywords

bevacizumab; capecitabine; clinical trial; docetaxel; gastric cancer; phase 2

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BEVACIZUMAB; CAPECITABINE; DOCETAXEL; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; PACLITAXEL; RAMUCIRUMAB; THYMIDYLATE SYNTHASE; TRASTUZUMAB; XERODERMA PIGMENTOSUM GROUP D PROTEIN; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); PLATINUM COMPLEX; TAXOID;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER RADIOTHERAPY; CHEMORADIOTHERAPY; CIRCULATING TUMOR CELL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DISEASE CONTROL; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRY SKIN; DYSPNEA; ESOPHAGUS PERFORATION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HAND FOOT SYNDROME; HUMAN; HUMAN CELL; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE GASTRIC CANCER; HYPERTENSION; HYPOKALEMIA; INFLAMMATION; LACRIMATION DISORDER; LEUKOPENIA; LUNG EMBOLISM; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MUCOSAL INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL SENSORY NEUROPATHY; PHARMACOGENETICS; PHASE 2 CLINICAL TRIAL; PNEUMOSEPSIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; SENSORY NEUROPATHY; SEPSIS; STOMACH CANCER; STOMACH HEMORRHAGE; STOMATITIS; TRANSLATIONAL RESEARCH; TREATMENT RESPONSE; CLINICAL TRIAL; DRUG ADMINISTRATION; GENETICS; MIDDLE AGED; PATHOLOGY; STOMACH NEOPLASMS; TUMOR EMBOLISM;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; CAPECITABINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; ORGANOPLATINUM COMPOUNDS; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; STOMACH NEOPLASMS; TAXOIDS;

EID: 84960426049     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29864     Document Type: Article

References (26)

1. World Health Organization. About page. http://www.who.int/. Accessed January 2, 2015.
2. Wagner AD, Unverzagt S, Grothe W, et al., Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2010; 3: CD004064.
3. Cunningham D, Starling N, Rao S, et al., Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008; 358: 36-46.
4. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al,; V325 Study Group. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006; 24: 4991-4997.
5. Ajani JA, Moiseyenko VM, Tjulandin S, et al,; V-325 Study Group. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group. J Clin Oncol. 2007; 25: 3210-3216.
6. Wang J, Xu R, Li J, et al., Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer [published online ahead of print January 21, 2015 ]. Gastric Cancer. doi: 10.1007/s10120-015-0457-4.
7. Deenen MJ, Meulendijks D, Boot H, et al., Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction [published online ahead of print October 23, 2015 ]. Cancer Chemother Pharmacol.
8. Ohtsu A, Shah MA, Van Cutsem E, et al., Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2011; 29: 3968-3976.
9. Shah MA,. Global perspectives in oncology: what have we learned in gastric cancer. Presented at: 51st Annual Meeting of American Society Of Clinical Oncology; May 29-June 2, 2015; Chicago, IL.
10. Simkens LH, van Tinteren H, May A, et al., Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet. 2015; 385: 1843-1852.
11. Qiu M, Wei X, Zhang D, et al., Efficacy and safety of capecitabine as maintenance treatment after first-line chemotherapy using oxaliplatin and capecitabine in advanced gastric adenocarcinoma patients: a prospective observation. Tumour Biol. 2014; 35: 4369-4375.
12. Eisenhauer EA, Therasse P, Bogaerts J, et al., New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45: 228-247.
13. Meulendijks D, Beerepoot LV, Boot H, et al., Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study. Invest New Drugs. 2016; 34: 119-128.
14. Pluim D, Devriese LA, Beijnen JH, Schellens JH,. Validation of a multiparameter flow cytometry method for the determination of phosphorylated extracellular-signal-regulated kinase and DNA in circulating tumor cells. Cytometry A. 2012; 81: 664-671.
15. Van Cutsem E, de Haas S, Kang YK, et al., Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol. 2012; 30: 2119-2127.
16. Miles DW, de Haas SL, Dirix LY, et al., Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer. Br J Cancer. 2013; 108: 1052-1060.
17. Li J, Qin S, Xu J, et al., Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. J Clin Oncol. 2013; 31: 3219-3225.
18. Fuchs CS, Tomasek J, Yong CJ, et al,; REGARD Trial Investigators. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2013; 6736: 31-39.
19. Yoon HH, Bendell JC, Braiteh FS, et al., Ramucirumab (RAM) plus FOLFOX as front-line therapy (Rx) for advanced gastric or esophageal adenocarcinoma (GE-AC): randomized, double-blind, multicenter phase 2 trial [abstract]. J Clin Oncol. 2014; 32 (suppl 5): Page. Abstract 4004.
20. Eren OO, Ozturk MA, Sonmez OU, Oyan B,. Safety, feasibility, and efficacy of capecitabine maintenance in patients with advanced gastric cancer: a retrospective study [published online ahead of print November 13, 2014 ]. Am J Ther.
21. Van Cutsem E, Boni C, Tabernero J, et al., Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study. Ann Oncol. 2015; 26: 149-156.
22. Uenosono Y, Arigami T, Kozono T, et al., Clinical significance of circulating tumor cells in peripheral blood from patients with gastric cancer. Cancer. 2013; 119: 3984-3991.
23. Frosst P, Blom HJ, Milos R, et al., A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995; 10: 111-113.
24. Shitara K, Muro K, Ito S, et al., Folate intake along with genetic polymorphisms in methylenetetrahydrofolate reductase and thymidylate synthase in patients with advanced gastric cancer. Cancer Epidemiol Biomarkers Prev. 2010; 19: 1311-1319.
25. Xia LZ, Liu Y, Xu XZ, et al., Methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and gastric cancer susceptibility. World J Gastroenterol. 2014; 20: 11429-11438.
26. Gu J, Zheng L, Wang Y, Zhu M, Wang Q, Li X,. Prognostic significance of HER2 expression based on trastuzumab for gastric cancer (ToGA) criteria in gastric cancer: an updated meta-analysis. Tumour Biol. 2014; 35: 5315-5321.